Innovative Delivery Platform Crossject's flagship product ZENEO® offers a needle-free autoinjector solution that enables rapid, easy administration of emergency medication, appealing to healthcare providers and emergency response services seeking non-invasive delivery options.

Expanding Product Pipeline With ongoing development of rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdoses, and asthma attacks, Crossject presents multiple opportunities to offer complementary solutions to healthcare providers managing acute conditions.

Strategic Partnerships and Funding Recent partnerships with Heights Capital and successful funding rounds demonstrate strong investor confidence and potential for scaling sales efforts through strategic alliances and increased resource availability.

Regulatory Momentum Advanced regulatory progress for ZEPIZURE® and other therapies signals market readiness, enabling sales teams to target hospitals, clinics, and emergency services with validated, approved products.

Emerging Market Presence Crossject's dual presence in France and the U.S., along with recent financings and product development achievements, positions it well to penetrate international markets, especially among healthcare systems prioritizing rapid, user-friendly treatment options.